S. Unizony

发表

The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial

J. Stone, Hyon K. Choi, N. Patel, 2021, Rheumatology and Therapy.

Improved survival in granulomatosis with polyangiitis: A general population-based study.

J. Stone, Hyon K. Choi, S. Unizony, 2016, Seminars in arthritis and rheumatism.

Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database

J. Best, S. Unizony, A. Kong, 2019, Rheumatology and Therapy.

Accuracy of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) As a Research Tool for Identification of Patients with Uveitis and Scleritis

R. Plenge, L. Sobrin, S. Unizony, 2015, Ophthalmic epidemiology.

Challenging mimickers of primary systemic vasculitis.

J. Stone, S. Unizony, E. Miloslavsky, 2015, Rheumatic diseases clinics of North America.

Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial

J. Stone, M. Aringer, D. Blockmans, 2021 .

New treatment strategies in large-vessel vasculitis

J. Stone, J. Stone, S. Unizony, 2013, Current opinion in rheumatology.

The heart in vasculitis.

S. Unizony, E. Miloslavsky, 2014, Rheumatic diseases clinics of North America.

Does Tocilizumab Influence Ophthalmic Outcomes in Giant Cell Arteritis?

Sashank Prasad, S. Unizony, F. Costello, 2022, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

Trial of Tocilizumab in Giant‐Cell Arteritis

J. Stone, M. Aringer, G. Schett, 2017, The New England journal of medicine.

Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial.

J. Stone, D. Blockmans, E. Brouwer, 2017, Seminars in arthritis and rheumatism.

Inpatient complications in patients with giant cell arteritis: decreased mortality and increased risk of thromboembolism, delirium and adrenal insufficiency.

J. Stone, S. Unizony, Mariano E. Menendez, 2015, Rheumatology.

Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations

J. Stone, J. Best, R. Spiera, 2021, Arthritis Research & Therapy.

Surgical site infection in hand surgery

Hyon K. Choi, D. Ring, S. Unizony, 2015, International Orthopaedics.

Lung involvement in ANCA-associated vasculitis

S. Unizony, A. Abril, 2022, Handbook of Systemic Autoimmune Diseases.

Myeloperoxidase–Antineutrophil Cytoplasmic Antibody (ANCA)–Positive and ANCA‐Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets

P. Merkel, J. Stone, C. Kallenberg, 2016, Arthritis & rheumatology.

Case Records of the Mass General Hospital. Case 7-2015: A 25-year-old man with oral ulcers, rash, and odynophagia.

M. Hoang, Nancy Kim, S. Unizony, 2015, The New England journal of medicine.

Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients

M. Alba, S. Unizony, M. Cid, 2017, RMD Open.

Clinical correlations with Porphyromonas gingivalis antibody responses in patients with early rheumatoid arthritis

A. Steere, T. Kawai, S. Unizony, 2013, Arthritis Research & Therapy.

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis

D. Blockmans, R. Luqmani, W. Schmidt, 2020, Rheumatology and Therapy.

Ustekinumab for the Treatment of Giant Cell Arteritis.

J. Stone, S. Unizony, Ana D. Fernandes, 2020, Arthritis care & research.

Ustekinumab for the Treatment of Giant Cell Arteritis

J. Stone, S. Unizony, J. Stone, 2020, Arthritis care & research.

Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab

J. Stone, M. Aringer, G. Schett, 2019, Arthritis & rheumatology.

OP0059 MAVRILIMUMAB (ANTI GM-CSF RECEPTOR Α MONOCLONAL ANTIBODY) REDUCES RISK OF FLARE AND INCREASES SUSTAINED REMISSION IN A PHASE 2 TRIAL OF PATIENTS WITH GIANT CELL ARTERITIS

J. Paolini, L. Pupim, S. Unizony, 2021 .

Rituximab for the Treatment of IgG4-Related Disease: Lessons From 10 Consecutive Patients

J. Stone, V. Deshpande, S. Unizony, 2012, Medicine.

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Eric A. Meyerowitz, Matthew J. Frigault, J. Stone, 2020, The New England journal of medicine.

S. Unizony, J. Stone, John H. Stone, 2021 .

Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial

I. Wicks, B. Trapnell, L. Dagna, 2022, Annals of the Rheumatic Diseases.

Acute fibrinous and organizing pneumonia in systemic lupus erythematosus: A case report and review of the literature

Amita Sharma, M. Mino‐Kenudson, J. Stone, 2010, Pathology international.

Pan American League of Associations for Rheumatology guidelines for the treatment of giant cell arteritis.

M. Scolnik, S. Unizony, A. Babini, 2022, The Lancet. Rheumatology.

Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type

P. Merkel, J. Stone, Hyon K. Choi, 2015, Annals of the rheumatic diseases.

Novel compound heterozygous variants in CECR1 gene associated with childhood onset polyarteritis nodosa and deficiency of ADA2.

S. Unizony, M. Hershfield, T. Caskey, 2016, Rheumatology.

Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2015, Arthritis & rheumatology.

Ocular inflammatory disease in patients with polymyalgia rheumatica: A case series and review of the literature

J. Stone, L. Sobrin, S. Unizony, 2014, Clinical Rheumatology.

Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica

S. Unizony, J. Stone, E. Miloslavsky, 2012, Arthritis care & research.

Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis

P. Merkel, Hyon K. Choi, G. Tómasson, 2017, Arthritis & rheumatology.

Evolving Use of Molecular Imaging in Research and in Practice

A. Tawakol, M. Osborne, S. Unizony, 2019, Arthritis & rheumatology.

Disease Activity, Glucocorticoid Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA‐Associated Vasculitis

C. Kallenberg, Hyon K. Choi, P. Monach, 2016 .

LB0006 SARILUMAB IN PATIENTS WITH RELAPSING POLYMYALGIA RHEUMATICA: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL (SAPHYR)

F. Buttgereit, R. Spiera, A. Rubbert-Roth, 2022, Annals of the Rheumatic Diseases.

An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy

J. Stone, A. Luster, S. Unizony, 2016, Annals of the rheumatic diseases.

New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension

J. Stone, M. Aringer, D. Blockmans, 2021, Rheumatology.

S. Unizony, J. Stone, Ana D. Fernandes, 2021 .

Treatment failure in giant cell arteritis

J. Stone, M. Bao, S. Unizony, 2021, Annals of the Rheumatic Diseases.

Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial.

J. Stone, R. Spiera, M. Bao, 2021, Seminars in arthritis and rheumatism.

IL-6 Blockade and its Therapeutic Success in Giant Cell Arteritis

S. Unizony, T. Kermani, 2018, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2017, Arthritis care & research.

Nationwide Trends in Hospitalizations and In‐Hospital Mortality in Granulomatosis With Polyangiitis (Wegener's)

J. Stone, Hyon K. Choi, S. Unizony, 2016, Arthritis care & research.

SAT0334 Nationwide Trends in Hospitalization and in-Hospital Mortality Associated with Anca-Associated Vasculitis (AAV)

S. Unizony, Z. Wallace, J. Stone, 2016 .

Pearls & Oy-sters: Neuro-Sweet disease presenting as ischemic stroke and aseptic meningitis

N. Rost, S. Unizony, N. Venna, 2018, Neurology.

Case 18-2023: A 19-Year-Old Woman with Dyspnea and Tachypnea.

E. Isselbacher, S. Unizony, V. Baliyan, 2023, The New England journal of medicine.

Design of the Tocilizumab in Giant Cell Arteritis Trial

J. Stone, J. Zwerina, G. Schett, 2013, International journal of rheumatology.

Giant Cell Arteritis and Polymyalgia Rheumatica: Treatment Approaches and New Targets.

M. Putman, S. Unizony, D. Nepal, 2023, Rheumatic diseases clinics of North America.

Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial

J. Stone, M. Aringer, D. Blockmans, 2019 .

Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis

S. Unizony, Shalini V. Mohan, N. Dagincourt, 2023, RMD Open.

POS0808 CHARACTERISTICS OF GIANT CELL ARTERITIS FLARES AFTER SUCCESSFUL TREATMENT WITH TOCILIZUMAB: RESULTS FROM THE LONG-TERM EXTENSION OF A RANDOMIZED CONTROLLED PHASE 3 TRIAL

J. Stone, S. Unizony, Jian Han, 2021 .

Pan American League of Associations for Rheumatology Guidelines for the Treatment of Takayasu Arteritis

M. Scolnik, S. Unizony, A. Babini, 2023, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica

S. Unizony, E. Miloslavsky, A. Khosroshahi, 2012, Arthritis care & research.

Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study.

S. Unizony, Ana D. Fernandes, M. Matza, 2023, The Lancet. Rheumatology.

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis

R. Spiera, S. Unizony, M. Nivens, 2023, Arthritis Research & Therapy.

J. Stone, S. Unizony, Ana D. Fernandes, 2020, Arthritis care & research.

274. CLINICAL OUTCOMES OF PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN REAL-WORLD CLINICAL PRACTICE

J. Stone, J. Best, S. Unizony, 2019, Rheumatology.

Pan American League of Associations for Rheumatology Guidelines for the treatment of ANCA-associated vasculitis.

M. Scolnik, S. Unizony, A. Babini, 2023, The Lancet. Rheumatology.

SAT0248 CLINICAL OUTCOMES OF PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN REAL-WORLD CLINICAL PRACTICE

J. Stone, J. Best, S. Unizony, 2019, Saturday, 15 June 2019.

Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.

G. Yancopoulos, R. Spiera, R. Bhore, 2023, The New England journal of medicine.

Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature

S. Unizony, O. Maíz, J. Loricera, 2024, Arthritis research & therapy.